GLP-1 Users Saw Lower Risks of Heart Attack and Stroke in Major Study
Summary
A study of more than 256,000 adults with prediabetes and obesity found that people prescribed GLP-1 drugs had lower rates of several health outcomes than people taking metformin. The observational study found associations, not proof that the drugs caused the differences, and an outside endocrinologist said factors such as health and access to care could have affected the results.Key Facts
- Researchers analyzed electronic health records for 256,492 adults in the TriNetX global health network.
- Participants had prediabetes and obesity, an average age of 52, and 76 percent were women.
- The study compared people prescribed GLP-1 drugs, including semaglutide and tirzepatide, with people taking metformin.
- GLP-1 users were about 1.5 times more likely to return their blood sugar to normal than metformin users.
- Compared with metformin users, GLP-1 users had a 31 percent lower risk of developing Type 2 diabetes and a 41 percent lower risk of death from any cause.
- GLP-1 users had 15 percent fewer heart attacks, 20 percent fewer strokes, 25 percent fewer cases of heart failure, and an 8 percent lower risk of atrial fibrillation.
- Researchers presented the findings at the American Heart Association's Scientific Sessions 2026.
- The study was observational, so it cannot establish that GLP-1 drugs caused the lower risks; differences between patients may have influenced the findings.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
